Clinical trials: SLE
Systemic Lupus Erythematosus
O-GlcNAcylation Role in the Pathophysiology of Systemic Lupus Erythematosus
This study aims at defining the role of O-GlcNAcylation is in the physiopathology of systemic lupus erythematosus (SLE). O-GlcNAcylation is a metabolic pathway potentially implicated in SLE with potential for the discovery of new…
- Trial name
- METABOLUPS (NCT04440566)
- Testing
- blood sample
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Bordeaux
Age-Related Macular Degeneration, Allergies
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and…
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease
- Trial name
- NCT05635266
- Testing
- Specimen sample
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Systemic Lupus Erythematosus
Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE
This is an investigator-initiated trial aimed at assessing the safety and efficacy of ultra-fast autologous CD19-targeted CAR-T cells in the treatment of refractory systemic lupus erythematosus.
- Trial name
- NCT07233642
- Testing
- CD19 CAR-T cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Lupus Erythematosus, Systemic, Lupus Nephritis
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
The purpose of this study is to evaluate the efficacy, safety and drug levels of CC-97540 in participants with active systemic lupus erythematosus (SLE) including lupus nephritis with inadequate response to glucocorticoids and at…
- Trial name
- NCT07015983
- Testing
- CC-97540, Fludarabine, Cyclophosphamide
- Where
- 97 sites in United States, Argentina and 14 more
- Volunteers
- 89 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
SARS-CoV-2, Systemic Lupus Erythematosus
Association Between Long-term Hydroxychloroquine Treatment and Outcome of a History of Symptoms Suggestive of COVID-19 Infection During the Epidemic Period in France in Patients With Autoimmune Disease
This epidemiological, transversal, cohort study aims to determine the potential influence of an active long-term hydroxychloroquine intake over the prevalence of a history of symptoms evocative of a COVID-19 infection in patients…
- Conditions
- SARS-CoV-2, Systemic Lupus Erythematosus, Rheumatoid Arthritis, Sjogren's Syndrome
- Trial name
- COVCALL (NCT04345159)
- Testing
- Questionnaire by phone call
- Where
- France
- Volunteers
- 572 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Systemic Lupus Erythematosus
Effect of Pioglitazone on Endothelial Function in Premenopausal Women With Uncomplicated Systemic Lupus Erythematosus
The present study aims to investigate the effect of pioglitazone (30 mg/day) on endothelial function in premenopausal women with SLE (systemic lupus erythematosus).
- Trial name
- NCT01322308
- Testing
- pioglitazone
- Volunteers
- 30 people
- Sponsor
- National Heart Institute, Mexico
Lupus Erythematosus
Identification of Modifiable Sleep-related Factors in Patients With Systemic Lupus Erythematosus.
Background: Sleep quality is a key determinant of physical and mental health, with important implications for immune regulation, psychological well-being, and overall quality of life.
- Trial name
- NCT07483541
- Testing
- Adults with systemic lupus erythematosus
- Where
- Spain
- Volunteers
- 250 people
- Sponsor
- Investigación en Hemofilia y Fisioterapia
Systemic Lupus Erythematosus
Autophagy in Systemic Lupus Erythematosus
Systemic lupus erythematosus is systemic autoimmune disease characterized by a wide range of clinical manifestations, from skin and mucosal lesions to severe injuries in the central nervous system, kidneys and other organs.
- Trial name
- NCT03583853
- Testing
- real time PCR
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assiut University
Systemic Lupus Erythematosus
Saphnelo Use in Females of Child-bearing Potential
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by substantial clinical burden-including organ damage, increased morbidity, and mortality-that often presents in young adulthood and…
- Trial name
- PRIMULA DUS (NCT07431775)
- Testing
- Anifrolumab
- Volunteers
- 26,000,000 people
- Sponsor
- AstraZeneca
Healthy Subjects (HS), SLE (Systemic Lupus)
First-in-Human Study of ISH0613: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics
The goal of this clinical trial is to learn about a study drug called ISH0613 and how it behaves in healthy adults. This study will also evaluate the safety and tolerability of ISH0613 after a single intravenous (IV) dose.
- Trial name
- NCT07516639
- Testing
- ISH0613 for injection
- Where
- China
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- SUNHO（China）BioPharmaceutical CO., Ltd.
Osteoporosis, Lupus Erythematosus, Systemic
Determination of the RANKL/Osteoprotegerin Ratio in Patients With Systemic Lupus Erythematosus. Role in Osteoporosis and Cardiovascular Calcification
Patients with Systemic lupus erythematosus (SLE) are known to present an increased risk of osteoporosis and cardiovascular calcification.
- Trial name
- CALCILUP (NCT02799173)
- Testing
- RANKL/OPG ratio, bone densitometry, fan beam CT scan
- Where
- 2 sites in France
- Volunteers
- 74 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Lupus Erythematosus, Systemic
A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus
The purpose of this Phase 2, multicenter, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of an oral treatment regimen of CC-220 versus placebo in adult subjects with active systemic lupus…
- Trial name
- NCT03161483
- Testing
- CC-220
- Where
- 184 sites in United States, Argentina and 13 more
- Volunteers
- 289 people
- Sponsor
- Celgene
H. Pylori, SLE - Systemic Lupus Erythematosus
Associating Gastric Infection With Autoimmune Flare Severity in an Egyptians
A cross-sectional, observational study aims to evaluate the relationship between Helicobacter pylori infection and disease activity in patients diagnosed with systemic lupus erythematosus (SLE), using a combination of structured…
- Trial name
- NCT07157202
- Volunteers
- 115 people
- Sponsor
- Assiut University
Systemic Lupus Erythematosus
Study of TRU-015 in Subjects With Membranous Nephropathy Secondary to Systemic Lupus Erythematosus
The purpose of this study is to determine how the body absorbs and chemically changes a single infusion of TRU-015 in subjects with kidney disease caused by lupus.
- Trial name
- NCT00479622
- Testing
- TRU-015
- Where
- 6 sites in United States
- Volunteers
- 20 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Systemic Lupus Erythematosus
Transcutaneous Vagus Nerve Stimulation in SLE
Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease. Joint and muscle pain and fatigue are extremely common among patients and contribute to a reduced quality of life.
- Trial name
- TvSSLE (NCT06987565)
- Testing
- Active vagus nerve stimulation
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Northwell Health
Lupus Erythematosus, Systemic
Efficacy and Safety of IL-1 Inhibitors in Mild to Moderate Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a systemic autoimmune disorder in which pro-inflammatory factors of the IL-1 family play a pivotal role in its pathogenesis.
- Trial name
- NCT07381465
- Testing
- Firsekibart
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Chinese SLE Treatment And Research Group
Systemic Lupus Erythematosus
A Phase Ib Study of QLS4131 in Subjects With Systemic Lupus Erythematosus
The goal of this open label, dose escalation phase 1b clinical trial is to investigate the safety, tolerability, pharmacokinetic, pharmacodynamics, immunogenicity and preliminary clinical efficacy of QLS4131 in subjects with…
- Trial name
- NCT07001839
- Testing
- QLS4131 for Injection.
- Volunteers
- 108 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Autoimmune Diseases
CAR-T Cells Therapy for Patients With Autoimmune Diseases
This is an open label, single-site, dose-escalation study in up to 18 participants with refractory autoimmune diseases. This study aims to evaluate the safety and efficacy of the treatment with Anti-BCMA and CD19 CART
- Trial name
- ECAR01 (NCT07052565)
- Testing
- Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Anhui Provincial Hospital
Systemic Lupus Erythematosus, Systemic Sclerosis
Nonmyeloablative Allo Stem Cell Transplant for Severe Autoimmune Diseases
Autoimmune diseases present a special challenge to clinicians and the aim of this protocol is to serve as a last-line effort for patients with unmanageable disease.
- Trial name
- NCT00849745
- Testing
- Nonmyeloablative allogeneic stem cell transplant
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Duke University
Systemic Lupus Erythematosus
Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus
The primary aim of the present study was to investigate the prevalence of low bone mineral density (BMD) and vertebral fractures, as determined by a standardized assessment, and to elucidate the role of bone qualities, including…
- Trial name
- NCT00668330
- Testing
- Ibandronate+alfacalcidol+calcium
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chinese University of Hong Kong